Aid in evaluation and management of multiple myeloma and related plasma cell disorders. Indicated for the diagnosis of patients with oligosecretory or nonsecretory multiple myeloma and light chain amyloidosis.
Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
After separation from cells: Ambient: Unacceptable; Refrigerated: 3 weeks; Frozen: 6 months
|Lambda Qnt Free Light Chains||Effective February 18, 2020
|Kappa Qnt Free Light Chains||Effective February 18, 2020
3.30 - 19.40 mg/L
|Kappa/Lambda Free Light Chain Ratio||0.26-1.65|
Undetected antigen excess is a rare event but cannot be excluded. Free light chain results should always be interpreted in conjunction with other clinical and laboratory findings.
No compliance statements are in use for this test.
This assay is highly sensitive to increasing concentrations of monoclonal free kappa or free lambda light chains in the serum of patients with evolving or relapsing myelomas.
|Component Test Code*||Component Chart Name||LOINC|
|0055168||Kappa Qnt Free Light Chains||36916-5|
|0055169||Lambda Qnt Free Light Chains||33944-0|
|0055179||Kappa/Lambda Free Light Chain Ratio||80517-6|
- Kappa Qnt Free Light Chains
- Kappa/Lambda Free Light Chain Ratio
- Lambda Qnt Free Light Chains